Biography
Andre Strydom is a specialist in the Psychiatry of Intellectual disabilities. Dr. Strydom's research has a specific focus on conditions associated with ageing in intellectual disability (ID) populations, such as Alzheimer's disease in individuals with Down Syndrome (DS). He is an expert in ageing-related issues and the cognitive phenotype(s) associated with trisomy 21.
Current projects and collaborations include the LonDownS consortium previously funded by the Wellcome Trust and currently funded by the MRC to study the development of Alzheimer's Disease in Down syndrome; other funders include the Baily Thomas Fund and the LeJeune Foundation. This work concerns detailed cognitive phenotyping of individuals with Down across the lifespan, and tracking change with ageing using MR, EEG and fNIRS neuroimaging, as well as collecting DNA, blood and cellular samples. His research includes identification of plasma biomarkers of cognitive decline including markers related to inflammation, amyloid processing, and oxidative stress. He is a founding member of the Horizon21 European clinical trial network for Alzheimer’s disease in Down syndrome.
Dr Strydom is also involved in developing and testing the efficacy of medication and complex interventions for the treatment of mental disorders in adults with intellectual disabilities and he leads the Neurodevelopmental disorders clinical trials centre (ND-CTC) in the FANS department which conducts phase II/III clinical trials for treatments of Autism, Down syndrome and other conditions.
He has been an investigator on industry sponsored trials of new drug treatment options in Down syndrome and fragile X syndrome.
Research Interests
- Down syndrome
- Alzheimer’s disease
- Intellectual disabilities
- Autism
Research Groups
- LonDowns Consortium
- AIMS-2-Trials https://www.aims-2-trials.eu
- Horizon21 Consortium
Expertise and Public Engagement
Chair of the Intellectual Disabilities Dementia Interest group - https://www.kcl.ac.uk/ioppn/depts/fans/research/dementia-in-intellectual-disabilities-special-interest-group-did-sig
President (in waiting) of the Trisomy 21 Research Society - https://www.t21rs.org
Executive Committee member, Society for the Study of Behavioural Phenotypes https://ssbp.org.uk/committee/
Description
- Mental Health in Intellectual Disabilities
- Health issues associated with Down syndrome
- Neurodevelopmental disorders
-
Veteleanu, A., Pape, S., Davies, K., Kodosaki, E., Hye, A., Zelek, W. M., Strydom, A. & Morgan, B. P., 2022, (Accepted/In press) In: Alzheimer's and Dementia. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1002/alz.12799
-
Aslam, A., Baksh, R. A., Pape, S., Strydom, A., Gulliford, M. & Chan, L., 30 Sep 2022, In: Diabetes Care. Research output: Contribution to journal › Article › peer-review
-
Pinku, H., Hüls, A., Feany, P. T., Baumer, N., Dierssen, M., Bargagna, S., Costa, A. C. S., Chicoine, B. A., Rebillat, A. S., Sgandurra, G., Valentini, D., Rohrer, R. T., Levin, J., Lakhanpaul, M., Carfì, A., Sherman, S. L., Strydom, A. & Ghosh, S., 8 Aug 2022, In: Journal of Global Health. 12, 05035. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.7189/jogh.12.05035
-
Saini, F., Dell' Acqua, F. & Strydom, A., 22 Jul 2022, In: Frontiers in Neuroscience. 16, 908413. Research output: Contribution to journal › Review article › peer-review. DOIs: https://doi.org/10.3389/fnins.2022.908413
-
Trisomy 21 Research Society COVID-19 Initiative, Apr 2022, In: Vaccines. 10, 4, 530. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.3390/vaccines10040530
-
Pape, S., Jones, L., Sadheura, K. & Strydom, A., 1 Jan 2021, The Neurobiology of Aging and Alzheimer Disease in Down Syndrome. Elsevier, p. 273-288 16 p. Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review. DOIs: https://doi.org/10.1016/B978-0-12-818845-3.00004-9
-
Baksh, R. A., Strydom, A., Pape, S. E., Chan, L. F. & Gulliford, M. C., Jun 2022, In: Journal of General Internal Medicine. 37, 8, p. 2009-2015 7 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1007/s11606-022-07420-9
-
Illouz, T., Biragyn, A., Frenkel-Morgenstern, M., Weissberg, O., Gorohovski, A., Merzon, E., Green, I., Iulita, F., Flores-Aguilar, L., Dierssen, M., De Toma, I., Lifshitz, H., Antonarakis, S. E., Yu, E., Herault, Y., Potier, M. C., Botté, A., Roper, R., Sredni, B., Sarid, R., & 4 othersLondon, J., Mobley, W., Strydom, A. & Okun, E., Dec 2021, In: NEUROMOLECULAR MEDICINE. 23, 4, p. 561-571 11 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1007/s12017-021-08651-5
-
MBBS FRCPCH DM on behalf of The Trisomy 21 Research Society COVID-19 Initiative Study Group, 1 Nov 2021, In: Journal of Clinical Medicine. 10, 21, 5125. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.3390/jcm10215125
-
Baksh, R. A., Pape, S. E., Smith, J. & Strydom, A., 4 Oct 2021, In: BMJ Open. 11, 10, e052482. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1136/bmjopen-2021-052482